A composition for improving, preventing and treating of chronic prostatitis or chronic pelvic pain syndrome comprising sanity cannabinoid

Abstract

The present invention relates to a composition for improving, preventing, or treating chronic prostatitis or chronic pelvic pain, and more specifically, by including two or more non-psychoactive cannabinoids selected from the group consisting of cannabidiol (CBD), cannabichromene (CBC), and cannabigerol (CBG) as active ingredients, it can improve, prevent, or treat chronic prostatitis or chronic pelvic pain, and thus can be utilized as a food composition, furthermore as a health functional food or pharmaceutical composition.

Description

Technology Field

[0001] The present invention relates to a composition capable of improving, preventing, or treating chronic prostatitis or chronic pelvic pain by including two or more non-psychoactive cannabinoids selected from the group consisting of cannabidiol (CBD), cannabichromene (CBC), and cannabigerol (CBG) as active ingredients. Background Technology

[0002] The prostate is a tissue found only in men, surrounding the urethra below the bladder. About the size of a chestnut, the prostate is an organ that produces and secretes approximately 30% of semen. Diseases resulting from problems with prostate function are broadly classified into four categories: benign prostatic hyperplasia, prostatitis, prostate cancer, and prostate stones.

[0003] The above-mentioned prostatitis is a general term for inflammatory symptoms caused by various factors affecting the prostate. It is a disease that 50% of adult men experience at least once and accounts for 25% of urology outpatient visits, making it a common male disease.

[0004] The above prostatitis is classified into four categories (acute bacterial prostatitis, chronic bacterial prostatitis, chronic prostatitis / chronic pelvic pain syndrome, and asymptomatic inflammatory prostatitis) according to the criteria of the National Institutes of Health (NIH).

[0005] Category I above refers to acute bacterial prostatitis accompanied by systemic symptoms such as urinary symptoms, pain, and fever caused by bacterial infection. Additionally, Category II refers to chronic bacterial prostatitis, which is a chronicized form of Category I, and is characterized by symptoms of recurrent bacterial infection. Furthermore, Category III is classified as chronic prostatitis / chronic pelvic pain syndrome, characterized by pain / discomfort in the pelvic region (such as the perineum, testes, penis, and lower abdomen) and urinary symptoms such as a sensation of residual urine and frequent urination. Meanwhile, Category IV refers to asymptomatic inflammatory prostatitis, which is asymptomatic but involves findings of inflammation in prostate biopsy tissue specimens, prostate exudate, or semen.

[0006] In addition, while the expression of IL-1β is significantly elevated in the semen of patients with chronic prostatitis, it has been reported that the expression of MIP-1α and MCP-1 is significantly elevated in the prostatic exudate of patients with chronic prostatitis.

[0007] However, unlike the acute bacterial prostatitis of category I and the chronic bacterial prostatitis of category II, the etiology of the above-mentioned category III chronic prostatitis / chronic pelvic pain syndrome is unknown, so no effective treatment method has been found.

[0008] Therefore, there is a need for a natural product-derived therapeutic agent that can improve, prevent, or treat the above-mentioned Category III chronic prostatitis / chronic pelvic pain syndrome with few side effects. Prior art literature

[0009] Republic of Korea Registered Patent No. 2218751, U.S. Published Patent No. 2022-0218877 The problem to be solved

[0010] The objective of the present invention is to provide a food composition capable of improving or preventing chronic prostatitis or chronic pelvic pain by including two or more non-psychoactive cannabinoids selected from the group consisting of cannabidiol (CBD), cannabichromene (CBC), and cannabigerol (CBG) as active ingredients.

[0011] In addition, another objective of the present invention is to provide a pharmaceutical composition capable of preventing or treating chronic prostatitis or chronic pelvic pain by including two or more non-psychoactive cannabinoids selected from the group consisting of cannabidiol (CBD), cannabichromene (CBC), and cannabigerol (CBG) as active ingredients. means of solving the problem

[0012] The food composition of the present invention for improving or preventing chronic prostatitis or chronic pelvic pain to achieve the above-mentioned purpose may include two or more non-psychoactive cannabinoids selected from the group consisting of cannabidiol (CBD), cannabichromene (CBC), and cannabigerol (CBG) as active ingredients.

[0013] The above composition may include a mixture of cannabidiol (CBD) and cannabichromene (CBC).

[0014] The above cannabidiol (CBD) and cannabichromene (CBC) can be mixed in a weight ratio of 1:0.1-5.

[0015] The above composition may include a mixture of cannabidiol (CBD) and cannabigerol (CBG).

[0016] The above cannabidiol (CBD) and cannabigerol (CBG) can be mixed in a weight ratio of 1:0.1-5.

[0017] The above composition may include a mixture of cannabidiol (CBD), cannabichromene (CBC), and cannabigerol (CBG).

[0018] The above cannabidiol (CBD), cannabichromene (CBC), and cannabigerol (CBG) can be mixed in a weight ratio of 1:0.1-5:0.1-5.

[0019] Two or more non-psychoactive cannabinoids selected from the group consisting of cannabidiol (CBD), cannabichromene (CBC), and cannabigerol (CBG) can be used at a concentration of 0.05 to 2.0 µg / ml.

[0020] Two or more non-psychoactive cannabinoids selected from the group consisting of cannabidiol (CBD), cannabichromene (CBC), and cannabigerol (CBG) may be obtained from cannabis.

[0021] In addition, the pharmaceutical composition of the present invention for the prevention or treatment of chronic prostatitis or chronic pelvic pain to achieve the other purpose mentioned above may include two or more non-psychoactive cannabinoids selected from the group consisting of cannabidiol (CBD), cannabichromene (CBC), and cannabigerol (CBG) as active ingredients. Effects of the invention

[0022] The composition of the present invention for improving, preventing, or treating chronic prostatitis or chronic pelvic pain includes two or more non-psychoactive cannabinoids selected from the group consisting of cannabidiol (CBD), cannabichromene (CBC), and cannabigerol (CBG) as active ingredients, and thus can improve, prevent, or treat chronic prostatitis or chronic pelvic pain, and can be utilized as a food composition, furthermore as a health functional food or pharmaceutical composition. Brief explanation of the drawing

[0023] Figure 1 is a graph showing the cell viability measured using CBD, CBC, and CBG of Comparative Examples 1 to 3. Figure 2a is a graph showing the quantitative measurement of the expression level of the inflammatory factor NF-kB when the mixture of Example 1 and the CBD of Comparative Example 1 were treated at 0.1 ug / ml. Figure 2b is a graph showing the quantitative measurement of the expression level of the inflammatory factor COX2 when the mixture of Example 1 and the CBD of Comparative Example 1 were treated at 0.1 ug / ml. Figure 2c is a graph showing the quantitative measurement of the expression level of the inflammatory factor NF-kB when the mixture of Example 1 and the CBD of Comparative Example 1 were treated at 0.1 ug / ml. Figure 3a is a Western blot showing the expression of the inflammatory factor NF-kB when CBC and CBG of Comparative Example 2 and Comparative Example 3 are treated at 0.1 ug / ml; Figure 3b is a graph quantitatively showing the expression level measured in Figure 3a. Specific details for implementing the invention

[0024] The present invention relates to a composition capable of improving, preventing or treating chronic prostatitis or chronic pelvic pain, comprising two or more non-psychoactive cannabinoids selected from the group consisting of Cannabidiol (CBD), Cannabichromene (CBC) and Cannabigerol (CBG) as an active ingredient.

[0026] Hereinafter, the present invention will be described in detail.

[0027] The composition for improving, preventing or treating chronic prostatitis or chronic pelvic pain of the present invention comprises two or more non-psychoactive cannabinoids selected from the group consisting of Cannabidiol (CBD), Cannabichromene (CBC) and Cannabigerol (CBG) as an active ingredient.

[0028] The non-psychoactive cannabinoids used in the present invention are each obtained from cannabis, and are a mixture of two or more non-psychoactive cannabinoids that are not psychoactive cannabinoids and can be used for recreational and medical purposes.

[0029] The cannabis (大麻, Cannabis sativa L.Cannabis chemovars, which is an annual plant of the genus Cannabis of the family Cannabaceae that has been widely cultivated in tropical and temperate regions, centered in Central Asia, for 12,000 years, including wild hemp, and Cannabis sativa subspecies sativa, Cannabis sativa subspecies indica, Cannabis sativa subspecies ruderalis, including Cannabis chemovars and their variants, varieties var. indica and var. kafiristanica, which contain various types of cannabinoid compounds known as medicinal and pharmaceutical components, as well as genetically crossed, self-crossed, or hybrid plants thereof.

[0030] The above-mentioned cannabidiol (CBD) is a compound with a molecular weight of 314.464 g / mol and a chemical formula of C21H30O2, and a drug called Epidiolex, which is a drug containing the above-mentioned cannabidiol, is approved by the U.S. Food and Drug Administration for the treatment of epilepsy. Long-term side effects of the above-mentioned drug include drowsiness, loss of appetite, diarrhea, fatigue, anxiety, lethargy, and sleep disorders.

[0031] In addition, the above cannabicromene (CBC) is produced when CBDA (cannabidiol acid) is broken down by exposure to heat or ultraviolet rays, and is effective in treating inflammation such as osteoarthritis when used together with tetrahydrocannabiol (THC).

[0032] In addition, the aforementioned cannabigenol (CBG) is a non-psychoactive cannabinoid that can be applied in various ways in the medical field; it lowers anxiety, depression, and intraocular pressure associated with glaucoma, blocks receptors that induce cancer cell growth, and combats Staphylococcus aureus (MRSA).

[0033] For example, the composition of the present invention may include a mixture of cannabidiol (CBD) and cannabicromene (CBC) mixed in a weight ratio of 1:0.1-5, preferably 1:0.5-3, as an active ingredient. When cannabidiol (CBD) and cannabicromene (CBC) are used separately without mixing, the effect of improving, preventing, or treating chronic prostatitis or chronic pelvic pain may be 10 to 80% lower compared to the mixture.

[0034] As another example, the composition of the present invention may include a mixture of cannabidiol (CBD) and cannabigerol (CBG) mixed in a weight ratio of 1:0.1-5, preferably 1:0.5-3, as an active ingredient. When cannabidiol (CBD) and cannabigerol (CBG) are used separately without mixing, the effect of improving, preventing, or treating chronic prostatitis or chronic pelvic pain may be 20 to 70% lower compared to the mixture.

[0035] As another example, the composition of the present invention may include a mixture of cannabidiol (CBD), cannabicromene (CBC), and cannabigerol (CBG) as an active ingredient in a weight ratio of 1:0.1-5:0.1-5, preferably 1:0.5-3:0.5-3. When cannabidiol (CBD), cannabicromene (CBC), and cannabigerol (CBG) are used individually without mixing, the improvement, prevention, or treatment effect of chronic prostatitis or chronic pelvic pain may be 20 to 90% lower compared to the mixture. Additionally, the composition containing the three types of non-psychotropic cannabinoids as active ingredients may improve the improvement, prevention, or treatment effect of chronic prostatitis or chronic pelvic pain by 5 to 40% compared to the composition containing the two types of non-psychotropic cannabinoids as active ingredients.

[0036] Two or more non-psychoactive cannabinoids selected from the group consisting of cannabidiol (CBD), cannabichromene (CBC), and cannabigerol (CBG) of the present invention are used at a concentration of 0.05 to 2.0 ug / ml, preferably 0.1 to 1.0 ug / ml. If the concentration is below the lower limit, the effect of improving, preventing, or treating chronic prostatitis or chronic pelvic pain may be significantly low, and if it exceeds the upper limit, toxicity may be induced and verification of safety is required.

[0038] Hereinafter, preferred embodiments are presented to aid in understanding the present invention; however, the following embodiments are merely illustrative of the invention, and it is obvious to those skilled in the art that various changes and modifications are possible within the scope and spirit of the invention, and that such variations and modifications fall within the scope of the appended claims.

[0039] Example 1.

[0040] Cannabidiol (CBD), cannabicromene (CBC), and cannabigerol (CBG) obtained from cannabis were mixed in a weight ratio of 1:0.5:0.5 to obtain a mixture.

[0042] Comparative Example 1. Cannabidiol (CBD)

[0043] Cannabidiol (CBD) obtained from cannabis was used.

[0045] Comparative Example 2. Cannabicromen (CBC)

[0046] Cannabis chromene (CBC) obtained from cannabis was used.

[0048] Comparative Example 3. Cannabizerol (CBG)

[0049] Cannabiserorol (CBG) obtained from cannabis was used.

[0051] <Test Example I> In vitro ( In vitro )

[0052] cell culture

[0053] RWPE-1 (ATCC, VA) was cultured in Dulbecco's modified Eagle medium (Gibco) containing low glucose supplemented with 20% fetal bovine serum (Gibco) and 5 ng / mL basal fibroblast growth factor (Cell Signaling Technology, Danvers) at 37 °C and 5% CO2. After 2 days, non-attached cells were removed and fresh medium was added. The culture medium was replaced every 2 days.

[0054] Test Example 1. Measurement of cell viability

[0055] To confirm cytotoxicity, the MTT (3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide) assay was performed, and normal cells were each 1.0 x 10⁶ 4 180 μL of the extract was dispensed into 96-well cell culture plates at a concentration of cells / mL and incubated in a cell incubator for 24 hours. The sample was diluted in DMEM and dispensed in 20 μL aliquots at each concentration; for the control group, an equal volume of DMEM was added instead of the extract, and the cells were incubated for an additional 24 hours. After removing the medium, 100 μL of MTT reagent was added to each well, and the cells were incubated in a cell incubator for 4 hours. Absorbance was measured at 570 nm using a microplate reader, and cell viability according to the treatment concentration of the sample was calculated according to Equation 1 below. The cytotoxicity criterion was set at a cell viability of less than 80% in accordance with the Ministry of Food and Drug Safety Notification No. 2015-82. *, p < 0.01; **, p < 0.05

[0056] [Mathematical Formula 1]

[0057]

[0058] Figure 1 is a graph showing the cell viability measured using CBD, CBC, and CBG of Comparative Examples 1 to 3.

[0059] As shown in Figure 1, it was confirmed that the cell viability of CBC and CBD was 80% or higher at 0.001 mg / ml, while the cell viability of CBG was less than 80% at 0.001 mg / ml, and it was confirmed that the cell viability decreased rapidly as the concentration increased.

[0061] Test Example 2. Measurement of Inflammatory Cytokines_Comparison of Example 1 and Comparative Example 1

[0062] administration of cannabinoids to RWPE-1 cells

[0063] Prostate cell line RWPE-1 cells were divided into four groups: (a) control group (RWPE-1, normal group), (b) LPS group (inflammation-induced), (c) CBD group (LPS-induced RWPE-1 treated with cannabidiol of Comparative Example 1), and (d) mixture group (LPS-induced RWPE-1 treated with the mixture of Example 1).

[0064] Cells in the CBD and mixture groups were treated with cannabinoids, whereas the control or LPS groups were treated only with an equal amount of cannabinoid diluent (DMSO). After cell attachment, RWPE-1 cells were induced with 10 μ / ml LPS for 24 hours and then treated with 0.1 μ / ml cannabinoids. After 24 hours, cells and supernatant were collected and analyzed using an ELISA kit.

[0065] RWPE-1 cells were homogenized using ice-cold RIPA buffer (Cell Signaling Technology, Danvers, US) containing a protease inhibitor cocktail and a phosphatase inhibitor cocktail (Roche Diagnostics GmbH) free of ethylenediaminetetraacetate. The homogenized sample was centrifuged at 12,000 xg for 10 minutes at 4°C, and the supernatant was extracted. The supernatant was electrophoresed on a NuPAGE 4%-12% bis-Tris gel (Invitrogen, Carlsbad, CA) and then transferred to a nitrocellulose membrane. After transfer, the membrane was blocked with 5% skim milk for 1 hour at room temperature and then incubated with the primary antibody.

[0066] The primary antibodies used were NF-κB (dilution 1:500; Cell Signaling Technology, Danvers, US), COX-2 (dilution 1:500; Cell Signaling Technology, Danvers, US), IL-8 (dilution 1:1000; Cell Signaling Technology, Danvers, US), TLR-4 (dilution 1:1000; Cell Signaling Technology, Danvers, US), GAPDH (dilution 1:5000; Abcam, Cambridge, UK), and horseradish peroxidase-conjugated secondary antibodies. The antibodies were incubated at room temperature for 1 hour. Proteins were detected using enhanced chemiluminescence (Amersham, Arlington Heights, IL). The obtained images were analyzed using Image J (National Institutes of Health, Bethesda, MD, US) to determine the combined density of each protein band.

[0067] Images were quantified using Image J (Media Cybernetics, Silver Spring, MD), and results were analyzed using SPSS 20.0 software (SPSS Inc, Chicago, IL). Measurements were expressed as mean ± SD, and multiple group comparisons were performed using ANOVA, followed by post-hoc comparisons using the Tukey-Kramer test. Data expressed as proportions were evaluated using the χ² test.

[0068] 2-1. IL-8 Measurement

[0069] Figure 2a is a graph showing the quantitative expression level of the inflammatory factor IL-8 when treated with the mixture of Example 1 and the CBD of Comparative Example 1 at 0.1 µg / ml. *p< 0.01 compared with the LPS group; **p< 0.01 compared with the LPS+CBD group

[0070] As shown in Fig. 2a, it was confirmed that the expression of IL-8 was further reduced when treated with the mixture of Example 1 compared to when treated with the CBD of Comparative Example 1.

[0072] 2-2. COX2 Measurement

[0073] Figure 2b is a graph showing the quantitative expression level of the inflammatory agent COX2 when treated with the mixture of Example 1 and CBD of Comparative Example 1 at 0.1 µg / ml. *p< 0.01 compared with the LPS group; **p< 0.01 compared with the LPS+CBD group

[0074] As shown in Fig. 2b, it was confirmed that the expression of COX2 was further reduced when treated with the mixture of Example 1 compared to when treated with CBD of Comparative Example 1.

[0076] 2-3. NF-kB Measurement

[0077] Figure 2c is a graph showing the quantitative expression level of the inflammatory factor NF-kB when treated with the mixture of Example 1 and CBD of Comparative Example 1 at 0.1 µg / ml. *p< 0.01 compared with the LPS group; **p< 0.01 compared with the LPS+CBD group

[0078] As shown in Fig. 2c, it was confirmed that the expression of NF-kB was further reduced when treated with the mixture of Example 1 compared to when treated with CBD of Comparative Example 1.

[0079] Based on the results of 2-1 to 2-3 above, it was confirmed that treatment with the mixture of Example 1 was more effective than treatment with CBD alone.

[0081] Test Example 3. Measurement of inflammatory cytokines_Comparative Examples 2 to 3

[0082] The experiment was conducted in the same manner as Experiment Example 2 above.

[0083] RWPE-1 cells were divided into four groups: (a) normal group (RWPE-1, normal group), (b) LPS group (inflammation induction), (c) CBC group (LPS-induced RWPE-1 treated with cannabicromen of Comparative Example 2), and (d) CBG group (LPS-induced RWPE-1 treated with cannabizerol of Comparative Example 3).

[0084] 3-1. NF-kB Measurement

[0085] Figure 3a is a Western blot showing the expression of the inflammatory factor NF-kB when CBC and CBG of Comparative Example 2 and Comparative Example 3 are treated at 0.1 ug / ml; Figure 3b is a graph quantitatively showing the expression level measured in Figure 3a.

[0086] As shown in Figures 3a and 3b, it was confirmed that NF-kB decreased in the groups administered CBC and CBG, respectively.

[0088] The following describes an example of a composition containing the powder of the present invention, but the present invention is not intended to be limited but merely to be described in detail.

[0089] Preparation Example 1. Preparation of a powder

[0090] 500 mg of the mixture of Example 1

[0091] 100 mg lactose

[0092] Talc 10 mg

[0093] The above ingredients are mixed and filled into an airtight bag to manufacture a powder.

[0095] Formulation Example 2. Preparation of tablets

[0096] 300 mg of the mixture of Example 1

[0097] 100 mg of corn starch

[0098] 100 mg lactose

[0099] Magnesium stearate 2 mg

[0100] After mixing the above ingredients, tablets are manufactured by compressing them according to the conventional method of manufacturing tablets.

[0102] Formulation Example 3. Preparation of capsules

[0103] 200 mg of the mixture of Example 1

[0104] Crystalline cellulose 3 mg

[0105] Lactose 14.8 mg

[0106] Magnesium stearate 0.2 mg

[0107] The above ingredients are mixed according to a conventional capsule manufacturing method and filled into a gelatin capsule to manufacture a capsule.

[0109] Formulation Example 4. Preparation of an injectable

[0110] 600 mg of the mixture of Example 1

[0111] Mannitol 180 mg

[0112] 2974 mg sterile distilled water for injection

[0113] Na2HPO 4, 12H2O 26 mg

[0114] It is manufactured with the above-mentioned ingredient content per ampoule according to the conventional method of manufacturing injectables.

[0116] Formulation Example 5. Preparation of a liquid formulation

[0117] 4 g of the mixture of Example 1

[0118] 10 g isomerized sugar

[0119] 5 g mannitol

[0120] Appropriate amount of purified water

[0121] According to the conventional method for manufacturing liquid preparations, each ingredient is added to purified water and dissolved, an appropriate amount of lemon scent is added, the above ingredients are mixed, purified water is added to adjust the total volume to 100g, and then the mixture is filled into a brown bottle and sterilized to produce the liquid preparation.

[0123] Formulation Example 6. Preparation of Granules

[0124] 1,000 mg of the mixture of Example 1

[0125] Appropriate amount of vitamin mixture

[0126] Vitamin A Acetate 70 µg

[0127] Vitamin E 1.0 mg

[0128] Vitamin B1 0.13 mg

[0129] Vitamin B2 0.15 mg

[0130] Vitamin B6 0.5 mg

[0131] Vitamin B12 0.2 µg

[0132] Vitamin C 10 mg

[0133] Biotin 10 µg

[0134] Nicotinamide 1.7 mg

[0135] Folic acid 50 µg

[0136] Calcium pantothenate 0.5 mg

[0137] Appropriate amount of mineral mixture

[0138] Ferrous sulfate 1.75 mg

[0139] Zinc oxide 0.82 mg

[0140] Magnesium carbonate 25.3 mg

[0141] 15 mg of dipotassium phosphate

[0142] 55 mg dicalcium phosphate

[0143] Potassium citrate 90 mg

[0144] Calcium carbonate 100 mg

[0145] Magnesium chloride 24.8 mg

[0146] Although the composition ratio of the above vitamin and mineral mixture is composed of ingredients relatively suitable for granules as a preferred example, the mixing ratio may be modified at will. The above ingredients may be mixed according to a conventional method for manufacturing granules, and then granules may be manufactured and used to manufacture a health functional food composition according to a conventional method.

[0148] Formulation Example 7. Preparation of a functional beverage

[0149] 1,000 mg of the mixture of Example 1

[0150] 1,000 mg citric acid

[0151] 100 g of oligosaccharide

[0152] 2 g of plum concentrate

[0153] 1 g of taurine

[0154] Add purified water to make a total of 900 mL

[0155] The above ingredients are mixed according to a conventional method for manufacturing health drinks, then stirred and heated at 85°C for about 1 hour, the resulting solution is filtered, obtained in a sterilized 2 L container, sealed and sterilized, and then refrigerated and used to manufacture the functional beverage composition of the present invention.

[0156] Although the above composition ratio was formulated by mixing ingredients relatively suitable for beverages as a preferred embodiment, the mixing ratio may be arbitrarily modified according to regional and ethnic preferences, such as consumer groups, countries of demand, and intended uses.

Claims

Claim 1 A food composition for the improvement or prevention of chronic prostatitis or chronic pelvic pain, characterized by containing as an active ingredient a non-psychoactive cannabinoid mixed with cannabidiol (CBD), cannabichromene (CBC), and cannabigerol (CBG) in a weight ratio of 1:0.1-5:0.1-5. Claim 2 delete Claim 3 delete Claim 4 delete Claim 5 delete Claim 6 delete Claim 7 delete Claim 8 A food composition for the improvement or prevention of chronic prostatitis or chronic pelvic pain, characterized in that, in claim 1, the non-psychoactive cannabinoid mixed with cannabidiol (CBD), cannabichromene (CBC), and cannabigerol (CBG) is used at a concentration of 0.05 to 2.0 µg / ml. Claim 9 A food composition for the improvement or prevention of chronic prostatitis or chronic pelvic pain, characterized in that, in claim 1, the non-psychoactive cannabinoids mixed with cannabidiol (CBD), cannabichromene (CBC), and cannabigerol (CBG) are obtained from cannabis. Claim 10 A pharmaceutical composition for the prevention or treatment of chronic prostatitis or chronic pelvic pain, characterized by comprising as an active ingredient a non-psychoactive cannabinoid mixed with cannabidiol (CBD), cannabichromene (CBC), and cannabigerol (CBG) in a weight ratio of 1:0.1-5:0.1-5. Claim 11 delete Claim 12 delete Claim 13 delete Claim 14 A pharmaceutical composition for the prevention or treatment of chronic prostatitis or chronic pelvic pain, characterized in that, in claim 10, the non-psychoactive cannabinoid mixture of cannabidiol (CBD), cannabichromene (CBC), and cannabigerol (CBG) is used at a concentration of 0.05 to 2.0 µg / ml.

Images